Blood Cancer Diagnostics Market Size, Growth & Forecast To 2033

Blood cancer diagnostics refers to the process of detecting and identifying cancers that affect the blood, bone marrow, and lymphatic systems, such as leukemia, lymphoma, and myeloma. These diagnostics involve a range of advanced techniques, including blood tests, flow cytometry, molecular testing, next-generation sequencing (NGS), and imaging technologies. Early and accurate detection is crucial for effective treatment and better patient outcomes. With advancements in AI-driven analysis and precision medicine, blood cancer diagnostics continue to evolve, offering improved accuracy and accessibility worldwide.

Government initiatives and awareness drive the global market

Government initiatives play a pivotal role in advancing the market by funding research focused on early detection and cutting-edge diagnostic technologies. These programs support the development of minimally invasive diagnostic methods and promote advancements in cancer genomics, AI, and ML, improving both early diagnosis and treatment outcomes. This proactive approach facilitates broader access to advanced diagnostics, fueling market growth.

In October 2024, IIT Bombay and the Tata Memorial Center made significant strides in CAR T-cell therapy for blood cancers, including Acute Lymphoblastic Leukemia (B-ALL) and Non-Hodgkin Lymphoma (B-NHL), with government grants and approval from the Drug Controller General of India (DCGI). These government-backed initiatives and collaborations in India are accelerating progress in blood cancer diagnostics and driving significant market growth.

Partnership and collaboration between various research institutes create tremendous opportunities

Strategic collaborations between biotech companies, research institutions, and healthcare providers are driving advancements in the blood cancer diagnostics market. These partnerships facilitate the development of cutting-edge diagnostic technologies, enabling earlier and more accurate detection while addressing unmet clinical needs.

• In October 2024, the Dana-Farber Cancer Institute collaborated with Johns Hopkins and Brigham and Women's Hospital to develop a CRISPR-based, point-of-care molecular diagnostic for acute promyelocytic leukemia and chronic myeloid leukemia.

By integrating research with clinical applications, such collaborations enhance accessibility to advanced diagnostics, fostering market expansion and improving patient care.

North America holds a leading position in the global blood cancer diagnostics market due to the availability of advanced technologies, infrastructure, high prevalence of blood cancer, funding and support from the government and private sectors, initiatives and awareness programs, and more. The region benefits from increasing R&D studies and trials, and technological advancements in diagnostic methods are driving the blood cancer diagnostic market. Moreover, a growing focus on cost-effective healthcare facilities further fuels the market's expansion.

Key Highlights

• The global blood cancer diagnostics market size was valued at USD 11.57 billion in 2024 and is projected to grow from USD 12.32 billion in 2025 to reach USD 18.27 billion by 2033, exhibiting a CAGR of 5.1% during the forecast period (2025-2033).
• Based on test type, the global blood cancer diagnostics market is segmented into blood tests, biopsy, imaging tests, and molecular tests. The blood test segment is the largest revenue contributor to the market.
• Based on product, the global blood cancer diagnostics market is segmented into instruments and assay kits & reagents. The instrumentssegment is the largest revenue contributor to the market.
• Based on end-users, the global market is segmented into hospitals, specialty clinics, diagnostic centers, and others. The hospital segment is the largest revenue contributor to the market.
• North America is the highest shareholder in the global market.

The key players in the global market are Abbott, Illumina, Inc., Bio-Rad Laboratories, Inc., Quest Diagnostics Incorporated, Invivoscribe, Inc., Adaptive Biotechnologies, SOPHiA GENETICS, SkylineDx, Bio-Techne, Danaher Corporation, F. Hoffmann-La Roche Ltd, Myriad Genetics Inc., NeoGenomics Laboratories, and others.

• April 2024- QIAGEN announced plans to introduce its QIAcuityDx system, a real-time PCR system for in vitro diagnostic testing, by the end of the year. Using this digital PCR technology, laboratories can produce and perform IVD assays or lab-developed tests (LDTs) to provide same-day results. This system aims to enhance the precision and speed of molecular diagnostics, including the detection of blood cancers.